-
Tytuł:
-
Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
-
Autorzy:
-
Wong ND; Heart Disease Prevention Program, University of California-Irvine, Irvine, CA, USA.
Fan W; Heart Disease Prevention Program, University of California-Irvine, Irvine, CA, USA.
Pak J; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
-
Źródło:
-
Diabetes & vascular disease research [Diab Vasc Dis Res] 2020 Jul-Aug; Vol. 17 (4), pp. 1479164120945674.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2009- : London : Sage Publications
Original Publication: Edgbaston, Birmingham, UK : Sherborne Gibbs, c2005-
-
MeSH Terms:
-
Clinical Decision-Making*
Eligibility Determination*
Patient Selection*
Benzhydryl Compounds/*therapeutic use
Cardiovascular Diseases/*prevention & control
Diabetes Mellitus, Type 2/*drug therapy
Glucosides/*therapeutic use
Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
Aged ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/mortality ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/mortality ; Disease Progression ; Female ; Heart Failure/mortality ; Heart Failure/prevention & control ; Hospitalization ; Humans ; Male ; Middle Aged ; Nutrition Surveys ; Protective Factors ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome ; United States/epidemiology
-
References:
-
N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
Circulation. 2017 Jul 18;136(3):249-259. (PMID: 28522450)
Diabetes Care. 2018 Jan;41(1):6-10. (PMID: 29263192)
Diabetes Ther. 2017 Apr;8(2):365-376. (PMID: 28324484)
Diab Vasc Dis Res. 2013 Nov;10(6):505-13. (PMID: 23975724)
Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123. (PMID: 30559236)
Diabetes Res Clin Pract. 2018 Feb;136:23-31. (PMID: 29196150)
Circulation. 2019 Jun 18;139(25):2822-2830. (PMID: 30955357)
N Engl J Med. 2016 Mar 17;374(11):1094. (PMID: 26981940)
Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145. (PMID: 29693360)
N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
Eur J Prev Cardiol. 2017 Oct;24(15):1637-1645. (PMID: 28870145)
N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223. (PMID: 30497881)
Am J Cardiol. 2014 Apr 15;113(8):1356-61. (PMID: 24581920)
Circulation. 2019 Sep 10;140(11):e563-e595. (PMID: 30879339)
Circulation. 2016 Sep 6;134(10):752-72. (PMID: 27470878)
Diabet Med. 2013 Mar;30(3):300-8. (PMID: 23075287)
N Engl J Med. 2019 Nov 21;381(21):1995-2008. (PMID: 31535829)
-
Contributed Indexing:
-
Keywords: Diabetes; cardiovascular disease; epidemiology; sodium glucose cotransporter 2
-
Substance Nomenclature:
-
0 (Benzhydryl Compounds)
0 (Glucosides)
0 (Sodium-Glucose Transporter 2 Inhibitors)
HDC1R2M35U (empagliflozin)
-
Entry Date(s):
-
Date Created: 20200730 Date Completed: 20200929 Latest Revision: 20210304
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC7510356
-
DOI:
-
10.1177/1479164120945674
-
PMID:
-
32722930
-
Aim: We examined eligibility and preventable cardiovascular disease events in US adults with diabetes mellitus from the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
Methods: We identified adults with diabetes mellitus eligible for EMPA-REG OUTCOME based on trial eligibility criteria available from the National Health and Nutrition Examination Surveys, 2007-2016. We estimated composite cardiovascular disease endpoints, as well as all-cause deaths, death from cardiovascular disease and hospitalizations for heart failure from trial treatment and placebo event rates, the difference indicating the preventable events.
Results: Among 29,629 US adults aged ⩾18 years (representing 231.9 million), 4672 (27.3 million) had diabetes mellitus, with 342 (1.86 million) meeting eligibility criteria of EMPA-REG OUTCOME. We estimated from trial primary endpoint event rates of 10.5% and 12.1% in the empagliflozin and placebo groups, respectively, that based on the 'treatment' of our 1.86 million estimated EMPA-REG OUTCOME eligible subjects, 12,066 (95% confidence interval: 10,352-13,780) cardiovascular disease events could be prevented annually. Estimated annual preventable deaths from any cause, cardiovascular causes and hospitalizations from heart failure were 17,078 (95% confidence interval: 14,652-19,504), 14,479 (95% confidence interval: 12,422-16,536) and 9467 (95% confidence interval: 8122-10,812), respectively.
Conclusion: Empagliflozin, if provided to EMPA-REG OUTCOME eligible US adults, may prevent many cardiovascular disease events, cardiovascular and total deaths, as well as heart failure hospitalizations.